Erlotinib entrapped in cholesterol-depleting cyclodextrin nanoparticles shows improved antitumoral efficacy in 3D spheroid tumors of the lung and the liver

References

• Tan S, Wang G. Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo. Drug Des Devel Ther. 2017;11:3519–3529.
   PubMed Web of Science ®Google Scholar
• Kelley RK, Ko AH. Erlotinib in the treatment of advanced pancreatic cancer. Biologics. 2008;2:83–95.
   PubMedGoogle Scholar
• Vrignaud S, Hureaux J, Wack S, et al. Design, optimization and in vitro evaluation of reverse micelle-loaded lipid nanocarriers containing erlotinib hydrochloride. Int J Pharm. 2012;436:194–200.
   PubMed Web of Science ®Google Scholar
• Kim J, Ramasamy T, Choi JY, et al. PEGylated polypeptide lipid nanocapsules to enhance the anticancer efficacy of erlotinib in non-small cell lung cancer. Colloids Surf B Biointerfaces. 2017;150:393–401.
   PubMed Web of Science ®Google Scholar
• van der Meel R, Sulheim E, Shi Y, et al. Smart cancer nanomedicine. Nat Nanotechnol. 2019;14:1007–1017.
   PubMed Web of Science ®Google Scholar
• Wolfram J, Ferrari M. Clinical cancer nanomedicine. Nano Today. 2019;25:85–98.
   PubMed Web of Science ®Google Scholar
• Li H, Qiu H, Wang J, et al. Erlotinib–silk fibroin nanoparticles in inhibiting tumor. Polym Bull. 2020;77:4325–4334.
   Web of Science ®Google Scholar
• Nottingham E, Sekar V, Mondal A, et al. The role of self-nanoemulsifying drug delivery systems of CDODA-Me in sensitizing erlotinib-resistant non-small cell lung cancer. J Pharm Sci. 2020;109:1867–1882.
   PubMed Web of Science ®Google Scholar
• Pandey P, Dua K, Dureja H. Erlotinib loaded chitosan nanoparticles: formulation, physicochemical characterization and cytotoxic potential. Int J Biol Macromol. 2019;139:1304–1316.
   PubMed Web of Science ®Google Scholar
• Crini G. Review: a history of cyclodextrins. Chem Rev. 2014;114:10940–10975.
   PubMed Web of Science ®Google Scholar
• Jansook P, Ogawa N, Loftsson T. Cyclodextrins: structure, physicochemical properties and pharmaceutical applications. Int J Pharm. 2018;535:272–284.
   PubMed Web of Science ®Google Scholar
• Bilensoy E, Gurkaynak O, Ertan M, et al. Development of nonsurfactant cyclodextrin nanoparticles loaded with anticancer drug paclitaxel. J Pharm Sci. 2008;97:1519–1529.
   PubMed Web of Science ®Google Scholar
• Cavalli R, Donalisio M, Civra A, et al. Enhanced antiviral activity of acyclovir loaded into beta-cyclodextrin-poly(4-acryloylmorpholine) conjugate nanoparticles. J Control Release. 2009;137:116–122.
   PubMed Web of Science ®Google Scholar
• Conte C, Scala A, Siracusano G, et al. Nanoassemblies based on non-ionic amphiphilic cyclodextrin hosting Zn(II)-phthalocyanine and docetaxel: design, physicochemical properties and intracellular effects. Colloids Surf B Biointerfaces. 2016;146:590–597.
   PubMed Web of Science ®Google Scholar
• Jiménez Blanco JL, Benito JM, Ortiz Mellet C, et al. Molecular nanoparticle-based gene delivery systems. J Drug Delivery Sci Technol. 2017;42:18–37.
   Web of Science ®Google Scholar
• Ünal H, d’Angelo I, Pagano E, et al. Core–shell hybrid nanocapsules for oral delivery of camptothecin: formulation development, in vitro and in vivo evaluation. J Nanopart Res. 2015;17:42.
   Web of Science ®Google Scholar
• da Rocha EL, Porto LM, Rambo CR. Nanotechnology meets 3D in vitro models: tissue engineered tumors and cancer therapies. Mater Sci Eng C Mater Biol Appl. 2014;34:270–279.
   PubMed Web of Science ®Google Scholar
• Chimento A, Casaburi I, Avena P, et al. Cholesterol and its metabolites in tumor growth: therapeutic potential of statins in cancer treatment. Front Endocrinol (Lausanne). 2018;9:807.
   PubMed Web of Science ®Google Scholar
• Huang B, Song B-l, Xu C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat Metab. 2020;2:132–141.
   PubMedGoogle Scholar
• Ünal S, Aktaş Y, Benito JM, et al. Cyclodextrin nanoparticle bound oral camptothecin for colorectal cancer: Formulation development and optimization. Int J Pharm. 2020;584:119468.
   PubMed Web of Science ®Google Scholar
• Varan G, Oncul S, Ercan A, et al. Cholesterol-targeted anticancer and apoptotic effects of anionic and polycationic amphiphilic cyclodextrin nanoparticles. J Pharm Sci. 2016;t105:3172–3182.
   PubMed Web of Science ®Google Scholar
• Dora CP, Trotta F, Kushwah V, et al. Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability. Carbohydr Polym. 2016;137:339–349.
   PubMed Web of Science ®Google Scholar
• ISO. ISO10993_5_2009. Biological evaluation of medical devices – part 5: tests for in vitro cytotoxicity. Geneva (Switzerland): ISO; 2009. Available from: http://www.dent.chula.ac.th/upload/images2/dent-bio-material/cytotoxicitytest/ISO10993_5_2009.pdf
   Google Scholar
• Babic A, Herceg V, Ateb I, et al. Tunable phosphatase-sensitive stable prodrugs of 5-aminolevulinic acid for tumor fluorescence photodetection. J Control Release. 2016;235:155–164.
   PubMed Web of Science ®Google Scholar
• Varan G, Patrulea V, Borchard G, et al. Cellular interaction and tumoral penetration properties of cyclodextrin nanoparticles on 3D breast tumor model. Nanomaterials (Basel). 2018;8:67.
   Google Scholar
• Alejandro MA, Marta GG, Annabelle G, et al. Monodisperse nanoparticles from self-assembling amphiphilic cyclodextrins: modulable tools for the encapsulation and controlled release of pharmaceuticals. Med Chem. 2012;8:524–532.
   PubMed Web of Science ®Google Scholar
• Deng S, Gigliobianco MR, Censi R, et al. Polymeric nanocapsules as nanotechnological alternative for drug delivery system: current status, challenges and opportunities. Nanomaterials (Basel). 2020;10:847.
   Google Scholar
• Erdoğar N, Akkın S, Bilensoy E. Nanocapsules for drug delivery: an updated review of the last decade. Recent Pat Drug Deliv Formul. 2018;12:252–266.
   PubMedGoogle Scholar
• Vaidya B, Parvathaneni V, Kulkarni NS, et al. Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer. Int J Biol Macromol. 2019;122:338–347.
   PubMed Web of Science ®Google Scholar
• Xu H, He C, Liu Y, et al. Novel therapeutic modalities and drug delivery – erlotinib liposomes modified with galactosylated lipid: in vitro and in vivo investigations. Artif Cells Nanomed Biotechnol. 2018;46:1902–1907.
   PubMed Web of Science ®Google Scholar
• Noorani M, Azarpira N, Karimian K, et al. Erlotinib-loaded albumin nanoparticles: a novel injectable form of erlotinib and its in vivo efficacy against pancreatic adenocarcinoma ASPC-1 and PANC-1 cell lines. Int J Pharm. 2017;531:299–305.
   PubMedGoogle Scholar
• Varan G, Varan C, Erdoğar N, et al. Amphiphilic cyclodextrin nanoparticles. Int J Pharm. 2017;531:457–469.
   PubMed Web of Science ®Google Scholar
• Pflueger I, Charrat C, Mellet CO, et al. Cyclodextrin-based facial amphiphiles: assessing the impact of the hydrophilic-lipophilic balance in the self-assembly, DNA complexation and gene delivery capabilities. Org Biomol Chem. 2016;14:10037–10049.
   PubMed Web of Science ®Google Scholar
• Letchford K, Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm. 2007;65:259–269.
   PubMed Web of Science ®Google Scholar
• Mora-Huertas CE, Fessi H, Elaissari A. Polymer-based nanocapsules for drug delivery. Int J Pharm. 2010;385:113–142.
   PubMed Web of Science ®Google Scholar
• Paiva AM, Pinto RA, Teixeira M, et al. Development of noncytotoxic PLGA nanoparticles to improve the effect of a new inhibitor of p53-MDM2 interaction. Int J Pharm. 2013;454:394–402.
   PubMedGoogle Scholar
• He C, Hu Y, Yin L, et al. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010;31:3657–3666.
   PubMed Web of Science ®Google Scholar
• Nichols JW, Bae YH. EPR: evidence and fallacy. J Control Release. 2014;190:451–464.
   PubMed Web of Science ®Google Scholar
• Danhier F. To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release. 2016;244:108–121.
   PubMed Web of Science ®Google Scholar
• Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63:131–135.
   PubMed Web of Science ®Google Scholar
• Verma A, Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small. 2010;6:12–21.
   PubMed Web of Science ®Google Scholar
• Behzadi S, Serpooshan V, Tao W, et al. Cellular uptake of nanoparticles: journey inside the cell. Chem Soc Rev. 2017;46:4218–4244.
   PubMed Web of Science ®Google Scholar
• Foroozandeh P, Aziz AA. Insight into cellular uptake and intracellular trafficking of nanoparticles. Nanoscale Res Lett. 2018;13:339.
   PubMed Web of Science ®Google Scholar
• Velpula A, Jukanti R, Janga KY, et al. Proliposome powders for enhanced intestinal absorption and bioavailability of raloxifene hydrochloride: effect of surface charge. Drug Dev Ind Pharm. 2013;39:1895–1906.
   PubMed Web of Science ®Google Scholar
• Varan G, Benito JM, Mellet CO, et al. Development of polycationic amphiphilic cyclodextrin nanoparticles for anticancer drug delivery. Beilstein J Nanotechnol. 2017;8:1457–1468.
   PubMed Web of Science ®Google Scholar
• Gadade DD, Pekamwar SS. Cyclodextrin based nanoparticles for drug delivery and theranostics. Adv Pharm Bull. 2020;10:166–183.
   PubMed Web of Science ®Google Scholar
• Reddy LH, Sharma RK, Chuttani K, et al. Etoposide-incorporated tripalmitin nanoparticles with different surface charge: formulation, characterization, radiolabeling, and biodistribution studies. AAPS J. 2004;6:55–64.
   Web of Science ®Google Scholar
• Makoni PA, Wa Kasongo K, Walker RB. Short term stability testing of efavirenz-loaded solid lipid nanoparticle (SLN) and nanostructured lipid carrier (NLC) dispersions. Pharmaceutics. 2019;11:397.
   PubMed Web of Science ®Google Scholar
• Gidwani B, Vyas A. A comprehensive review on cyclodextrin-based carriers for delivery of chemotherapeutic cytotoxic anticancer drugs. Biomed Res Int. 2015;2015:198268.
   PubMed Web of Science ®Google Scholar
• Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16:71.
   PubMed Web of Science ®Google Scholar
• Wong PT, Choi SK. Mechanisms of drug release in nanotherapeutic delivery systems. Chem Rev. 2015;115:3388–3432.
   PubMed Web of Science ®Google Scholar
• Talevi A, Gantner ME, Ruiz ME. Applications of nanosystems to anticancer drug therapy (Part I. Nanogels, nanospheres, nanocapsules). Recent Pat Anticancer Drug Discov. 2014;9:83–98.
   PubMed Web of Science ®Google Scholar
• Grosse PY, Bressolle F, Pinguet F. In vitro modulation of doxorubicin and docetaxel antitumoral activity by methyl-beta-cyclodextrin . Eur J Cancer. 1998;34:168–174.
   PubMed Web of Science ®Google Scholar
• Mohammad N, Malvi P, Meena AS, et al. Cholesterol depletion by methyl-β-cyclodextrin augments tamoxifen induced cell death by enhancing its uptake in melanoma. Mol Cancer. 2014;13:204.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26.
   PubMed Web of Science ®Google Scholar
• Tang J, Salama R, Gadgeel SM, et al. Erlotinib resistance in lung cancer: current progress and future perspectives. Front Pharmacol. 2013;4:15.
   PubMed Web of Science ®Google Scholar
• Chen Q, Pan Z, Zhao M, et al. High cholesterol in lipid rafts reduces the sensitivity to EGFR-TKI therapy in non-small cell lung cancer. J Cell Physiol. 2018;233:6722–6732.
   PubMed Web of Science ®Google Scholar
• Fenyvesi F, Fenyvesi E, Szente L, et al. P-glycoprotein inhibition by membrane cholesterol modulation. Eur J Pharm Sci. 2008;34:236–242.
   PubMed Web of Science ®Google Scholar
• de Vries NA, Buckle T, Zhao J, et al. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs. 2012;30:443–449.
   PubMed Web of Science ®Google Scholar
• Kim JB. Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol. 2005;15:365–377.
   PubMed Web of Science ®Google Scholar
• Thoma CR, Zimmermann M, Agarkova I, et al. 3D cell culture systems modeling tumor growth determinants in cancer target discovery. Adv Drug Deliv Rev. 2014;69–70:29–41.
   PubMed Web of Science ®Google Scholar
• Hakanson M, Textor M, Charnley M. Engineered 3D environments to elucidate the effect of environmental parameters on drug response in cancer. Integr Biol (Camb). 2011;3:31–38.
   PubMed Web of Science ®Google Scholar
• Fennema E, Rivron N, Rouwkema J, et al. Spheroid culture as a tool for creating 3D complex tissues. Trends Biotechnol. 2013;31:108–115.
   PubMed Web of Science ®Google Scholar
• Valente I, del Valle LJ, Casas MT, et al. Nanospheres and nanocapsules of amphiphilic copolymers constituted by methoxypolyethylene glycol cyanoacrylate and hexadecyl cyanoacrylate units. Express Polym Lett. 2013;7:2–20.
   Web of Science ®Google Scholar
• Bilensoy E, Sarisozen C, Esendağli G, et al. Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors. Int J Pharm. 2009;371:170–176.
   PubMed Web of Science ®Google Scholar
• Erdoğar N, Iskit AB, Eroğlu H, et al. Antitumor efficacy of bacillus calmette-guerin loaded cationic nanoparticles for intravesical immunotherapy of bladder tumor induced rat model. J Nanosci Nanotechnol. 2015;15:10156–10164.
   PubMed Web of Science ®Google Scholar
• Stylianopoulos T, Soteriou K, Fukumura D, et al. Cationic nanoparticles have superior transvascular flux into solid tumors: insights from a mathematical model. Ann Biomed Eng. 2013;41:68–77.
   PubMed Web of Science ®Google Scholar
• Frohlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomedicine. 2012;7:5577–5591.
   PubMed Web of Science ®Google Scholar